Comparison
Alpha-Lipoic Acid vs Nicotinamide Riboside
Side-by-side of Alpha-Lipoic Acid and Nicotinamide Riboside. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Alpha-Lipoic Acid
Alpha lipoic acid supplement guide: 600 mg/day oral dosing, R-ALA vs racemic absorption, neuropathy trial data, antioxidant mechanism, interactions.
Nicotinamide Riboside
Nicotinamide riboside (NR) is the most-studied NAD+ precursor in humans. Sold as Niagen by Chromadex; raises plasma NAD+ 30-60% at 250-1,000 mg/day.
Effects at a glance
Alpha-Lipoic Acid
- •Approved Rx for diabetic neuropathy in Germany at 600 mg/day IV (Thioctacid) since 1960s
- •Improves neuropathy symptoms (TSS, NIS) at 600 mg/day IV across ALADIN and SYDNEY trials
- •R-ALA enantiomer absorbs 40-100% better than racemic mixtures
- •Activates AMPK; produces small HbA1c reductions in T2DM
- •Plasma half-life ~30 minutes; split dosing or sustained-release is standard
- •Hypoglycemia risk with insulin or sulfonylureas; medication adjustment may be required
Nicotinamide Riboside
- •Most-studied NAD+ precursor in human trials; the original Niagen formulation by Chromadex
- •Plasma NAD+ rises 30-60% at 250-1,000 mg/day across multiple human PK trials
- •Martens 2018 reported reduced BP and arterial stiffness at 500 mg/day for 6 weeks
- •Dollerup 2018 found no insulin sensitivity change despite plasma NAD+ rise
- •Tissue NAD+ rise inconsistent; hard clinical endpoints not yet measured
- •Larger human safety database than NMN; comparable mechanistic effects
Side-by-side
| Attribute | Alpha-Lipoic Acid | Nicotinamide Riboside |
|---|---|---|
| Category | supplement | supplement |
| Also known as | ALA, thioctic acid, R-ALA, R-lipoic acid | NR, Niagen, nicotinamide riboside chloride |
| Half-life (hr) ↗ | 0.5 | 8 |
| Typical dose (mg) ↗ | 600 | 500 |
| Dosing frequency | 1 to 3 times daily on empty stomach | daily, typically morning |
| Routes | oral, iv | oral |
| Onset (hr) | 0.5 | 1 |
| Peak (hr) | 1 | 4 |
| Molecular weight | 206.33 | 255.25 |
| Molecular formula | C8H14O2S2 | C11H15N2O5 |
| Mechanism | Dual lipid- and water-soluble antioxidant; redox cycles with dihydrolipoic acid (DHLA) to scavenge ROS, regenerate vitamin E and C, and chelate transition metals. Activates AMPK in liver and muscle; cofactor for pyruvate and alpha-ketoglutarate dehydrogenase complexes. | NAD+ precursor via salvage pathway. Phosphorylated to NMN by nicotinamide riboside kinase (NRK), then converted to NAD+. Substrate for sirtuins, PARPs, and CD38. |
| Legal status | Dietary supplement (US, UK, Canada, most EU); prescription drug for diabetic neuropathy in Germany | OTC dietary supplement |
| WADA status | allowed | allowed |
| DEA / Rx | Not scheduled | OTC supplement |
| Pregnancy | Insufficient data; precautionary avoidance | Insufficient data at supplement doses |
| CAS | 62-46-4 | 1341-23-7 |
| PubChem CID | 864 | 439924 |
| Wikidata | Q161227 | Q3343054 |
Safety profile
Alpha-Lipoic Acid
Common side effects
- nausea
- abdominal discomfort
- diarrhea
- sulfurous odor
- rash (rare)
Contraindications
- pregnancy and lactation (insufficient safety data)
- active insulin autoimmune syndrome predisposition
Interactions
- insulin and sulfonylureas: additive hypoglycemia; medication dose adjustment may be required(major)
- thyroid hormone: may reduce T4 to T3 conversion at high doses(moderate)
- biotin: ALA competes with biotin uptake; chronic use can induce biotin insufficiency(minor)
- iron supplements: ALA chelates iron and reduces absorption; separate dosing(moderate)
- chemotherapy (oxidative-stress-dependent agents): theoretical interference; coordinate with oncology team(moderate)
Nicotinamide Riboside
Common side effects
- mild GI upset (rare)
- headache (rare)
Contraindications
- pregnancy / lactation (insufficient data)
- active cancer (theoretical, no contraindicating data)
Interactions
- pterostilbene: complementary sirtuin pathway (Basis combination)(minor)
- TMG (trimethylglycine): methylation support during high NAD+ precursor dosing(minor)
Which Should You Take?
Nicotinamide Riboside comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Alpha-Lipoic Acid is the right call when one of the conditionals below applies.
- → If your priority is long-term neuroprotection, pick Alpha-Lipoic Acid.
- → If your priority is energy and stamina, pick Nicotinamide Riboside.
- → If your priority is metabolic health and glucose control, pick Nicotinamide Riboside.
Edge case: Half-lives differ materially (Alpha-Lipoic Acid ~0.5 hr vs Nicotinamide Riboside ~8 hr). Nicotinamide Riboside reaches steady state faster; Alpha-Lipoic Acid is easier to dial in if tolerability is uncertain.
Default choice: Nicotinamide Riboside. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Alpha-Lipoic Acid only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Alpha-Lipoic Acid and Nicotinamide Riboside?
Alpha-Lipoic Acid and Nicotinamide Riboside differ in category (supplement vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Alpha-Lipoic Acid or Nicotinamide Riboside?
Alpha-Lipoic Acid half-life is 0.5 hours; Nicotinamide Riboside half-life is 8 hours.
Can you stack Alpha-Lipoic Acid with Nicotinamide Riboside?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper